Edge Wealth Management LLC trimmed its holdings in shares of Merck & Company, Inc. (NYSE:MRK) by 0.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,515 shares of the company’s stock after selling 99 shares during the period. Edge Wealth Management LLC’s holdings in Merck & were worth $1,507,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Cascade Investment Advisors Inc. increased its stake in shares of Merck & by 15.5% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after purchasing an additional 232 shares in the last quarter. Vigilant Capital Management LLC increased its stake in shares of Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after purchasing an additional 250 shares in the last quarter. Harbour Capital Advisors LLC purchased a new position in shares of Merck & during the 1st quarter worth approximately $127,000. Mascoma Wealth Management LLC increased its stake in shares of Merck & by 8.2% during the 2nd quarter. Mascoma Wealth Management LLC now owns 2,474 shares of the company’s stock worth $159,000 after purchasing an additional 187 shares in the last quarter. Finally, Gradient Investments LLC increased its stake in shares of Merck & by 17.5% during the 2nd quarter. Gradient Investments LLC now owns 2,710 shares of the company’s stock worth $174,000 after purchasing an additional 404 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.
Merck & Company, Inc. (NYSE:MRK) opened at 63.78 on Thursday. Merck & Company, Inc. has a one year low of $58.29 and a one year high of $66.80. The firm has a market cap of $173.95 billion, a price-to-earnings ratio of 34.53 and a beta of 0.80. The firm has a 50 day moving average of $64.46 and a 200-day moving average of $63.70.
Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. During the same quarter in the prior year, the business posted $0.93 EPS. Merck &’s quarterly revenue was up .9% on a year-over-year basis. Equities research analysts forecast that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, October 6th. Stockholders of record on Friday, September 15th were paid a dividend of $0.47 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.95%. Merck &’s dividend payout ratio (DPR) is 76.11%.
TRADEMARK VIOLATION NOTICE: “Edge Wealth Management LLC Sells 99 Shares of Merck & Company, Inc. (MRK)” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/10/12/edge-wealth-management-llc-sells-99-shares-of-merck-company-inc-mrk.html.
Several analysts have commented on the stock. Cowen and Company reaffirmed a “hold” rating and issued a $70.00 target price on shares of Merck & in a research note on Friday, September 1st. Zacks Investment Research cut shares of Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “sell” rating and issued a $52.00 target price on shares of Merck & in a research note on Sunday, August 20th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $74.00 target price (up from $70.00) on shares of Merck & in a research note on Thursday, July 27th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and issued a $66.00 target price (up from $64.00) on shares of Merck & in a research note on Monday, July 17th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $69.69.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.